Facebook Linkedin RSS Twitter Youtube
Home 2025

Pfizer

JPM: More “Smaller, Smarter” M&A Deals Expected in 2025, EY Predicts
GEN Edge

JPM: More “Smaller, Smarter” M&A Deals Expected in 2025, EY Predicts

Force of Nature: Enveda Raises $130M, Advances Lead Pipeline Candidate
Artificial Intelligence

Force of Nature: Enveda Raises $130M, Advances Lead Pipeline Candidate

Xiaorong He on Boehringer Ingelheim’s Investments in AI, Broader Applications in Pharma
Artificial Intelligence

Xiaorong He on Boehringer Ingelheim’s Investments in AI, Broader Applications in Pharma

StockWatch: Vaccine, ETF Shares Drop as Trump Chooses RFK Jr. for HHS
Drug Discovery

StockWatch: Vaccine, ETF Shares Drop as Trump Chooses RFK Jr. for HHS

Recursion Advances AI-Based C. Diff Candidate to Phase II
GEN Edge

Recursion Advances AI-Based C. Diff Candidate to Phase II

Novartis, Monte Rosa Launch Up-to-$2.1B Molecular Glue Collaboration
Drug Discovery

Novartis, Monte Rosa Launch Up-to-$2.1B Molecular Glue Collaboration

StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate
GEN Edge

StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate

Pfizer, Triana Launch Up-to-$1.5B+ Molecular Glue Collaboration
Drug Discovery

Pfizer, Triana Launch Up-to-$1.5B+ Molecular Glue Collaboration

StockWatch: Investors Unfazed by Illumina’s MiSeq Product Launches, Starboard’s $1B Stake in Pfizer
GEN Edge

StockWatch: Investors Unfazed by Illumina’s MiSeq Product Launches, Starboard’s $1B Stake in Pfizer

Pfizer Withdraws SCD Drug Oxbryta after EMA Discloses 16 Deaths in Trials
Drug Discovery

Pfizer Withdraws SCD Drug Oxbryta after EMA Discloses 16 Deaths in Trials

123...10Page 1 of 10
Copyright © 2025 Genetic Engineering & Biotechnology News. All Rights Reserved.